Literature DB >> 12215016

Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice.

Jun-ichi Miyagi1, Masato Masuda, Nobuyuki Takasu, Akitoshi Nagasaki, Tetsuharu Shinjyo, Hiroshi Uezato, Naoki Kakazu, Yuetsu Tanaka.   

Abstract

Primary effusion lymphoma (PEL) is recognized as a unique lymphoma entity, which occurs exclusively in body cavities as a serous lymphomatous effusion without tumor formation or organ infiltration. We established a cell line of B-cell origin from a pericardial effusion of a 63-year-old Japanese PEL patient who did not have human immunodeficiency virus infection. This PEL cell line had human herpesvirus-8 (HHV-8) and Epstein-Barr virus (EBV) infection. We named this cell line RM-P1. This cell line showed complex chromosomal abnormalities that could not be identified by G-banding. However, spectral karyotyping analysis determined the origin and organization of all unidentified chromosomal abnormalities. When inoculated into the peritoneal cavity of 8 severe combined immunodeficiency (SCID) mice depleted of natural killer cells, RM-P1 cells induced solid tumor with ascites in all animals tested. These tumor and ascitic cells had the same immunogenotypic features as those of the original RM-P1. These 2 types of cells were positive for both HHV-8 and EBV as demonstrated using polymerase chain reaction. Fluorescence-activated cell sorting analyses showed that neither tumors nor ascitic cells grown in SCID mice expressed leukocyte function-associated antigen (LFA)-1alpha (CD11a), LFA-1lbeta (CD18), LFA-2 (CD2), LFA-3 (CD58), intercellular adhesion molecule (ICAM)-1 (CD54), ICAM-2 (CD102), ICAM-3 (CD50), or leukocyte endothelial adhesion molecule (LECAM)-1 (CD62L), suggesting that these cytoadhesion molecules are not involved in tumor formation of RM-P1 cells in vivo. The establishment of the RM-P1 cell line and the animal model of PEL may provide insights for understanding the relationship between these viruses and PEL and for understand the mechanism for PEL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215016     DOI: 10.1007/BF02982580

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  46 in total

Review 1.  Human herpesvirus-8-associated body cavity-based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm.

Authors:  D S Karcher; S Alkan
Journal:  Hum Pathol       Date:  1997-07       Impact factor: 3.466

2.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

3.  Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

Authors:  P S Moore; C Boshoff; R A Weiss; Y Chang
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

Review 4.  Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?

Authors:  F Neipel; J C Albrecht; B Fleckenstein
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome.

Authors:  N Kakazu; M Taniwaki; S Horiike; K Nishida; T Tatekawa; M Nagai; T Takahashi; T Akaogi; J Inazawa; M Ohki; T Abe
Journal:  Genes Chromosomes Cancer       Date:  1999-12       Impact factor: 5.006

6.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

7.  Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells.

Authors:  M A Davis; M A Stürzl; C Blasig; A Schreier; H G Guo; M Reitz; S R Opalenik; P J Browning
Journal:  J Natl Cancer Inst       Date:  1997-12-17       Impact factor: 13.506

8.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

Review 9.  Body-cavity-based lymphoma in an elderly AIDS-unrelated male.

Authors:  T Okada; H Katano; H Tsutsumi; T Kumakawa; M Sawabe; T Arai; S Mori; M Mori
Journal:  Int J Hematol       Date:  1998-06       Impact factor: 2.490

10.  Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions.

Authors:  G Gaidano; K Cechova; Y Chang; P S Moore; D M Knowles; R Dalla-Favera
Journal:  Leukemia       Date:  1996-07       Impact factor: 11.528

View more
  5 in total

Review 1.  Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.

Authors:  Antonino Carbone; Ethel Cesarman; Annunziata Gloghini; Hans G Drexler
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

2.  Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.

Authors:  H Goto; R Kariya; E Kudo; Y Okuno; K Ueda; H Katano; S Okada
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

3.  Human herpesvirus 8 (HHV8) sequence variations in HHV8 related tumours in Okinawa, a subtropical island in southern Japan.

Authors:  K Kamiyama; T Kinjo; K Chinen; T Iwamasa; H Uezato; J-I Miyagi; N Mori; N Yamane
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

4.  Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma.

Authors:  Hiroki Goto; Yuki Kojima; Hirokazu Nagai; Seiji Okada
Journal:  Int J Hematol       Date:  2013-04-21       Impact factor: 2.490

5.  Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus.

Authors:  Madori Osawa; Sohtaro Mine; Shinichiro Ota; Kengo Kato; Tsuyoshi Sekizuka; Makoto Kuroda; Michiyo Kataoka; Hitomi Fukumoto; Yuko Sato; Takayuki Kanno; Hideki Hasegawa; Keiji Ueda; Masashi Fukayama; Takuya Maeda; Soichiro Kanoh; Akihiko Kawana; Yuji Fujikura; Harutaka Katano
Journal:  Infect Agent Cancer       Date:  2016-08-17       Impact factor: 2.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.